BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17158824)

  • 1. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
    Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P
    Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
    Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
    J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
    Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
    Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
    Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
    Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study.
    Sihvonen S; Korpela M; Mustonen J; Huhtala H; Karstila K; Pasternack A
    J Rheumatol; 2006 Sep; 33(9):1740-6. PubMed ID: 16881099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF; Michaud K; Wolfe F
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
    Raaschou P; Simard JF; Holmqvist M; Askling J;
    BMJ; 2013 Apr; 346():f1939. PubMed ID: 23568792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmö, Sweden.
    Bergström U; Jacobsson LT; Turesson C
    Rheumatology (Oxford); 2009 Dec; 48(12):1600-5. PubMed ID: 19858122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis.
    Radovits BJ; Fransen J; Al Shamma S; Eijsbouts AM; van Riel PL; Laan RF
    Arthritis Care Res (Hoboken); 2010 Mar; 62(3):362-70. PubMed ID: 20391482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
    Raaschou P; Simard JF; Neovius M; Askling J;
    Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.
    Pallavicini FB; Caporali R; Sarzi-Puttini P; Atzeni F; Bazzani C; Gorla R; Marchesoni A; Favalli EG; Montecucco C
    Autoimmun Rev; 2010 Jan; 9(3):175-80. PubMed ID: 19647103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
    Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
    J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.